On 10 May 2012, the European Journal of Hospital Pharmacy published a multi-authored research article in relation to stability studies of anticancer drugs.

The starting point of the article is that stability studies performed by the pharmaceutical industry are only designed to fulfil licensing requirements. This can lead to a need for additional stability data covering practical uses of anticancer drugs e.g. post-dilution or reconstitution stability data.

A European consensus conference was held in France in May 2010, under the auspices of the French Society of Oncology Pharmacy (SFPO), to propose adapted rules on stability in practical situations and guidelines for performing corresponding stability studies.

The considerations and recommendations arising from that conference are then explored in full in the Journal article.

Article here